Vitrolife signs collaboration agreement with University of Melbourne regarding development of stem cell media
Vitrolife has entered into a two year collaboration agreement with University of Melbourne regarding collaboration with the stem cells expertise of the development of clinical grade stem cell media.
“The regenerative medicine area is rapidly growing both within industry and academia. There is today an unmet need of high quality clinical grade stem cell media”, says Magnus Nilsson, Vitrolife’s CEO.
“University of Melbourne has a unique expertise within stem cells, above all in the field of pluripotent stem cells and as such is a valuable resource in developing the right products for a rapidly growing market”, says Anna Mårtensson, Head of Stem Cell business area at Vitrolife.
June 14, 2010
Gothenburg
Magnus Nilsson
CEO
Queries should be addressed to:
Magnus Nilsson, CEO; phone +46 31 721 80 61
Eva Nilsagård, CFO, phone +46 31 721 80 13
________________________________________________________________________________________________________________________________ Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body order to select usable organs and keeping them in optimal condition while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes. Vitrolife today has approximately 170 employees and the company’s products are sold in more than 85 markets. The company is headquartered in Gothenburg, Sweden, and there are subsidiaries in USA, Australia, France, Italy, United Kingdom and Japan. Production facilities are housed in Sweden and USA. The Vitrolife share is listed on NASDAQ OMX Nordic Exchange, Small Cap. ________________________________________________________________________________________________________________________________ Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00. Fax: +46 31 721 80 99. E-mail: info@vitrolife.com. Homepage: www.vitrolife.com. This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.